| Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. | |
| | |
MedLine Citation:
|
PMID: 17010798 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The goal of this work was to determine whether the blockade of histamine H2 receptors is beneficial for the pathophysiology of chronic heart failure (CHF). BACKGROUND: Because CHF is one of the major life-threatening diseases, we need to find a novel effective therapy. Intriguingly, our previous study, which predicts the involvement of histamine in CHF, suggests that we should test this hypothesis in patients with CHF. METHODS: We selected 159 patients who received famotidine among symptomatic CHF patients for the retrospective study. We blindly selected age- and gender-matched CHF patients receiving drugs for gastritis other than histamine H2 receptor blockers as a control group. For the prospective study, 50 symptomatic CHF patients were randomly divided into 2 groups. One group received famotidine of 30 mg/day for 6 months, and the other group received teprenone. RESULTS: In the retrospective study, famotidine of 20 to 40 mg decreased both left ventricular end-diastolic and end-systolic lengths (LVDd and LVDs, respectively) and the plasma B-type natriuretic peptide (BNP) levels (182 +/- 21 vs. 259 +/- 25 pg/ml, p < 0.05) with unaltered fractional shortening (FS). In a randomized, open-label study, compared with teprenone, famotidine of 30 mg prospectively decreased both New York Heart Association functional class (p < 0.05) and plasma BNP levels (183 +/- 26 pg/ml vs. 285 +/- 41 pg/ml, p < 0.05); this corresponded to decreasing both LVDd (57 +/- 2 mm vs. 64 +/- 2 mm, p < 0.05) and LVDs (47 +/- 2 mm vs. 55 +/- 2 mm, p < 0.05) with unaltered FS (15 +/- 1% vs. 17 +/- 1%). The frequency of readmission because of worsening of CHF was lower in the famotidine group (4% and 24%, p < 0.05). On the other hand, teprenone had no effects on CHF. CONCLUSIONS: Famotidine improved both cardiac symptoms and ventricular remodeling associated with CHF. Histamine H2 receptor blockers may have therapeutic benefits for CHF. |
| | |
Authors:
|
Jiyoong Kim; Akiko Ogai; Satoshi Nakatani; Kazuhiko Hashimura; Hideaki Kanzaki; Kazuo Komamura; Masanori Asakura; Hiroshi Asanuma; Soichiro Kitamura; Hitonobu Tomoike; Masafumi Kitakaze |
Related Documents
:
|
15882668 - Early brain natriuretic peptide increase reflects acute myocardial ischemia in patients... 12628948 - Changes in brain natriuretic peptide and norepinephrine over time and mortality and mor... 18057888 - Interventricular mechanical dyssynchrony determines abnormal heightening of plasma n-te... 18067448 - Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review. 9296398 - Continuous cardiac output monitoring during adult liver transplantation: thermal filame... 2224938 - Occlusion time dependency of regional noradrenaline release and cardiac arrhythmias dur... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2006-09-14 |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 48 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-10-02 Completed Date: 2006-10-12 Revised Date: 2007-04-04 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1378-84 Citation Subset: AIM; IM |
Affiliation:
|
Cardiovascular Division, National Cardiovascular Center, Suita City, Osaka Pref, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Cardiac Output, Low / drug therapy*, physiopathology* Chronic Disease Famotidine / therapeutic use* Female Gastroesophageal Reflux / drug therapy Histamine H2 Antagonists / therapeutic use* Humans Male Prospective Studies Receptors, Histamine H2 / physiology Retrospective Studies Ventricular Dysfunction, Left / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Histamine H2 Antagonists; 0/Receptors, Histamine H2; 76824-35-6/Famotidine |
| Comments/Corrections | |
Comment In:
|
J Am Coll Cardiol. 2007 Mar 13;49(10):1107; author reply 1107-8
[PMID:
17349895
]
J Am Coll Cardiol. 2006 Oct 3;48(7):1385-6 [PMID: 17010799 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease ...
Next Document: Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfun...